Market research
LXRX Lexicon Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 3.856
- Dividend yield
- Not available
- Beta
- 1.03
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US5288723027
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 3.856
- Dividend yield
- Not available
- Beta
- 1.03
About
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LXRX discussion.
5 years, 4 months ago
Lexicon Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 12.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 26.7.
Lexicon Pharmaceuticals, Inc's total revenue sank by 97.7% to $199K since the same quarter in the previous year.
Its net income has increased by 89.3% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 40.3% to $-34M since the same quarter in the previous year.
Based on the above factors, Lexicon Pharmaceuticals, Inc gets an overall score of 2/5.